MedTrace Logo

Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.

NCT05266300 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 722

Last updated 2022-11-01

No results posted yet for this study

Summary

The purpose of this study is to examine the benefits of a clinical implementation of a DPYD-genotype test to patients starting treatment with fluoropyrimidines (Fluorouracil (5-FU), capecitabine, tegafur).

Conditions

Interventions

GENETIC

DPYD genotype

The SNPs included in this study are the following (dbSNP Reference SNP) rs3918290(c.1905+1G\>A) rs67376798(c.2846A\>T) rs55886062(c.1679T\>G) rs56038477(75017182)/(c.1236G\>A)

Sponsors & Collaborators

  • Odense University Hospital

    collaborator OTHER

  • University of Southern Denmark

    lead OTHER

Principal Investigators

  • Per Damkier, MD, PhD · University of Southern Denmark

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2022-06-01
Completion
2022-10-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05266300 on ClinicalTrials.gov